Claus Spies, MD
Nephrology · Melbourne, FLNPI 1619952769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 24.9% of the total.
Across 143 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$873
- Bayer$639
- Fresenius USA Marketing, Inc.$250
- Amgen$212
- Nxstage Medical, Inc.$206
- OPKO Pharmaceuticals, LLC$195
- plus $1K from 18 others
Across 4 payments — averaging $212,705 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$774K
- Vertex$77K
What the payments were for
- Food & beverage$3,45199%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 51 | $873 |
| Bayer | 19 | $639 |
| Fresenius USA Marketing, Inc. | 13 | $250 |
| Amgen(2 entities) | 6 | $212 |
| Nxstage Medical, Inc. | 2 | $206 |
| OPKO Pharmaceuticals, LLC | 10 | $195 |
| Otsuka America Pharmaceutical, Inc. | 8 | $163 |
| Travere Therapeutics, Inc. | 2 | $144 |
| Vantive US Healthcare LLC | 2 | $130 |
| Akebia Therapeutics Inc | 6 | $127 |
| Baxter Healthcare | 1 | $104 |
| Vifor Pharma, Inc. | 6 | $100 |
| Mallinckrodt Hospital Products Inc. | 3 | $61 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Novartis | 2 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $34 |
| Boehringer Ingelheim | 1 | $32 |
| Ardelyx, Inc. | 1 | $28 |
| Amarin Pharma, Inc. | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $23 |
| GSK | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - PD$217
- Kerendia$125
- KRYSTEXXA$125
- NXSTAGE SYSTEM ONE$118
- PUREFLOW SL$118
How this compares
$3,504 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 18 | $23,670 |
| JardianceEmpagliflozin | 25 | $20,771 |
| KerendiaFinerenone | 17 | $18,343 |
| Sevelamer Carbonate | 31 | $9,499 |
| Calcium Acetate | 58 | $6,621 |
| ProsolParenteral Amino Acid 20% No.1 | 35 | $5,160 |
| Potassium Citrate ErPotassium Citrate | 17 | $2,940 |
| Hydralazine Hcl | 97 | $1,665 |
| Clonidine | 14 | $1,601 |
| Potassium Chloride | 81 | $1,374 |
| Bumetanide | 26 | $1,279 |
| Doxazosin Mesylate | 35 | $1,062 |
| Losartan Potassium | 81 | $1,020 |
| Amlodipine Besylate | 94 | $919 |
| Calcitriol | 57 | $850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $873 | $23,67018 claims |
| Boehringer IngelheimJardiance | $32 | $20,77125 claims |
| BayerKerendia | $639 | $18,34317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.
Other nephrology in Melbourne
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.